Skip to main content
SpringerLink
Log in

Economic Evaluation of Ropinirole Prolonged Release for Treatment of Parkinson’s Disease in The Netherlands

  • Short Communication
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Background

By using the findings obtained from the PREPARED study, we aimed to estimate the cost effectiveness of ropinirole prolonged release (PR) [Requip-Modutab®] in Parkinson’s disease (PD) versus ropinirole immediate release (IR). In the PREPARED study, ropinirole PR provided a significantly greater improvement in time spent ‘off’ than ropinirole IR when used as an add-on to levodopa.

Methods

A health state transition model was developed—based on Hoehn and Yahr (HY) stages in PD—to compare the two treatment strategies. The Markov model included the following treatment-related aspects: (i) rate of disease progression; (ii) rates of dyskinesia; and (iii) medication adherence.

Results

In our approach, the base-case analysis showed a favourable pharmacoeconomic profile of ropinirole PR versus ropinirole IR. In particular, general cost savings were estimated combined with modest gains in quality of life, due to reduced disease progression and lower dyskinesia rates. Sensitivity analyses showed that this result was rather robust for varying parameters deterministically, although cost savings were lost in some instances. In particular, the treatment benefits of lower dyskinesia rates and improved adherence influenced the cost-effectiveness outcome. Nonetheless, the cost effectiveness remained acceptable within the limits that were investigated. Probabilistic sensitivity analysis revealed that the probability of accepting PR over IR exceeded 95 % for all relevant ‘willingness-to-pay’ thresholds.

Conclusion

The results of our study indicate a high likelihood of ropinirole PR being cost saving or at least being considered cost effective for use in the Netherlands. However, claims included in our model regarding dyskinesia and improved medication adherence should be further supported by data from daily practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet. 2009;373:2055–66.

    Article  CAS  PubMed  Google Scholar 

  2. Weintraub D, Comella CL, Horn S. Parkinson’s disease—part 1: pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manag Care. 2008;14:S40–8.

    PubMed  Google Scholar 

  3. Klotsche J, Reese JP, Winter Y, Oertel WH, Irving H, Wittchen HU, Rehm J, Dodel R. Trajectory classes of decline in health-related quality of life in Parkinson’s disease: a pilot study. Value Health. 2011;14:329–38.

    Article  PubMed  Google Scholar 

  4. Winter Y, von Campenhausen S, Gasser J, Seppi K, Reese JP, Pfeiffer KP, Botzel K, Oertel WH, Dodel R, Poewe W. Social and clinical determinants of quality of life in Parkinson’s disease in Austria: a cohort study. J Neurol. 2010;257:638–45.

    Article  PubMed  Google Scholar 

  5. Bloem BR, Van Laar T, Keus SHJ, De Beer H, Poot E, Buskens E, Aarden W, Munneke M, on behalf of the Centrale Werkgroep Multidisciplinaire Richtlijn Parkinson 2006–2009. Multidisciplinaire richtlijn ziekte van Parkinson [in Dutch]. http://www.cbo.nl/Downloads/880/rl_parkinson_10.pdf. Accessed 5 Aug 2010.

  6. de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5:525–35.

    Article  PubMed  Google Scholar 

  7. de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran JM, Alperovitch A, Rocca WA. Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s Disease. J Neurol Neurosurg Psychiatry. 1997;62:10–5.

    Article  PubMed Central  PubMed  Google Scholar 

  8. de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology. 2004;63:1240–4.

    Article  PubMed  Google Scholar 

  9. de Lau LM, Schipper CM, Hofman A, Koudstaal PJ, Breteler MM. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch Neurol. 2005;62:1265–9.

    Article  PubMed  Google Scholar 

  10. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, Giladi N, Holloway RG, Moore CG, Wenning GK, Yahr MD, Seidl L. Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19:1020–8.

    Article  PubMed  Google Scholar 

  11. Shulman LM, Gruber-Baldini AL, Anderson KE, Vaughan CG, Reich SG, Fishman PS, Weiner WJ. The evolution of disability in Parkinson disease. Mov Disord. 2008;23:790–6.

    Article  PubMed  Google Scholar 

  12. Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, Taylor RL, Sanchez-Ramos J, O’Brien CF. Ropinirole for the treatment of early Parkinson’s disease. The Ropinirole Study Group. Neurology. 1997;49:393–9.

    Article  CAS  PubMed  Google Scholar 

  13. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson’s disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2002;58:11–7.

    Article  CAS  PubMed  Google Scholar 

  14. Lieberman A, Olanow CW, Sethi K, Swanson P, Waters CH, Fahn S, Hurtig H, Yahr M. A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease. Ropinirole Study Group. Neurology. 1998;51:1057–62.

    Article  CAS  PubMed  Google Scholar 

  15. Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ, Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:983–95.

    Article  CAS  PubMed  Google Scholar 

  16. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med. 2000;342:1484–91.

    Article  CAS  PubMed  Google Scholar 

  17. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–310.

    Article  CAS  PubMed  Google Scholar 

  18. Watts RL, Lyons KE, Pahwa R, Sethi K, Stern M, Hauser RA, Olanow W, Gray AM, Adams B, Earl NL, 228 Study Investigators. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson’s disease. Mov Disord. 2010;25:858–66.

    Article  PubMed  Google Scholar 

  19. Stocchi F, Giorgi L, Hunter B, Schapira AH. PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson’s disease. Mov Disord. 2011;26:1259–65.

    Article  PubMed  Google Scholar 

  20. Palmer CS, Nuijten MJ, Schmier JK, Subedi P, Snyder EH. Cost effectiveness of treatment of Parkinson’s disease with entacapone in the United States. Pharmacoeconomics. 2002;20:617–28.

    Article  PubMed  Google Scholar 

  21. Health Care Insurance Board. Dutch pharmacoeconomic guidelines [in Dutch]. http://www.cvz.nl/binaries/live/cvzinternet/hst_content/nl/documenten/rubriek+zorgpakket/cfh/richtlijnen+farmaco-economisch+onderzoek+-+engels.pdf (2004). Accessed 30 Dec 2011.

  22. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA. Guideline for costing research, methods and standardized prices for economic evaluations in health care [in Dutch]. 2004.

  23. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). http://www.ispor.org/peguidelines/index.asp. Date last accessed: 30 Dec 2011.

  24. Nuijten MJ, van Iperen P, Palmer C, van Hilten BJ, Snyder E. Cost-effectiveness analysis of entacapone in Parkinson’s disease: a Markov process analysis. Value Health. 2001;4:316–28.

    Article  CAS  PubMed  Google Scholar 

  25. Spottke EA, Volkmann J, Lorenz D, Krack P, Smala AM, Sturm V, Gerstner A, Berger K, Hellwig D, Deuschl G, Freund HJ, Oertel WH, Dodel RC. Evaluation of healthcare utilization and health status of patients with Parkinson’s disease treated with deep brain stimulation of the subthalamic nucleus. J Neurol. 2002;249:759–66.

    Article  CAS  PubMed  Google Scholar 

  26. Smala AM, Spottke EA, Machat O, Siebert U, Meyer D, Kohne-Volland R, Reuther M, DuChane J, Oertel WH, Berger KB, Dodel RC. Cabergoline versus levodopa monotherapy: a decision analysis. Mov Disord. 2003;18:898–905.

    Article  PubMed  Google Scholar 

  27. Siebert U, Bornschein B, Walbert T, Dodel RC. Systematic assessment of decision models in Parkinson’s disease. Value Health. 2004;7:610–26.

    Article  PubMed  Google Scholar 

  28. Hudry J, Rinne JO, Keranen T, Eckert L, Cochran JM. Cost-utility model of rasagiline in the treatment of advanced Parkinson’s disease in Finland. Ann Pharmacother. 2006;40:651–7.

    Article  CAS  PubMed  Google Scholar 

  29. Hjelmgren J, Ghatnekar O, Reimer J, Grabowski M, Lindvall O, Persson U, Hagell P. Estimating the value of novel interventions for Parkinson’s disease: an early decision-making model with application to dopamine cell replacement. Parkinsonism Relat Disord. 2006;12:443–52.

    Article  PubMed  Google Scholar 

  30. Eggert KM, Reese JP, Oertel WH, Dodel R. Cost effectiveness of pharmacotherapies in early Parkinson’s disease. CNS Drugs. 2008;22:841–60.

    Article  PubMed  Google Scholar 

  31. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13:397–409.

    Article  CAS  PubMed  Google Scholar 

  32. Postma MJ, Boersma C. Flexibility of Markov modeling for clinical pharmacoeconomics: illustration for cost-effectiveness in early Parkinson’s disease. Expert Rev Clin Pharmacol. 2012;5:1–4.

    Article  PubMed  Google Scholar 

  33. Bala MV, Mauskopf JA. Optimal assignment of treatments to health states using a Markov decision model: an introduction to basic concepts. Pharmacoeconomics. 2006;24:345–54.

    Article  PubMed  Google Scholar 

  34. Gold SJ, Hoang CV, Potts BW, Porras G, Pioli E, Kim KW, Nadjar A, Qin C, LaHoste GJ, Li Q, Bioulac BH, Waugh JL, Gurevich E, Neve RL, Bezard E. RGS9-2 negatively modulates l-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson’s disease. J Neurosci. 2007;27:14338–48.

    Article  CAS  PubMed  Google Scholar 

  35. Di Rocco A, Molinari SP, Kollmeier B, Yahr MD. Parkinson’s disease: progression and mortality in the l-DOPA era. Adv Neurol. 1996;69:3–11.

    PubMed  Google Scholar 

  36. Palmer CS, Schmier JK, Snyder E, Scott B. Patient preferences and utilities for ‘off-time’ outcomes in the treatment of Parkinson’s disease. Qual Life Res. 2000;9:819–27.

    Article  CAS  PubMed  Google Scholar 

  37. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson’s disease: non-l-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20:190–9.

    Article  PubMed  Google Scholar 

  38. Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G. Parkinson disease and risk of mortality: a prospective comorbidity-matched cohort study. Neurology. 2008;70:1423–30.

    Article  CAS  PubMed  Google Scholar 

  39. Herlofson K, Lie SA, Arsland D, Larsen JP. Mortality and Parkinson disease: a community based study. Neurology. 2004;62:937–42.

    Article  PubMed  Google Scholar 

  40. Davey P, Rajan N, Lees M, Aristides M. Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson’s disease: a decision-analytic model. Value Health. 2001;4:308–15.

    Article  CAS  PubMed  Google Scholar 

  41. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology. 2001;56:S1–88.

    Article  CAS  PubMed  Google Scholar 

  42. Schrag A, Ben-Shlomo Y, Quinn NP. Cross sectional prevalence survey of idiopathic Parkinson’s disease and Parkinsonism in London. BMJ. 2000;321:21–2.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. Sharma JC, Macnamara L, Hasoon M, Vassallo M, Ross I. Cascade of levodopa dose and weight-related dyskinesia in Parkinson’s disease (LD-WD-PD cascade). Parkinsonism Relat Disord. 2006;12:499–505.

    Article  PubMed  Google Scholar 

  44. Spottke AE, Reuter M, Machat O, Bornschein B, von Campenhausen S, Berger K, Koehne-Volland R, Rieke J, Simonow A, Brandstaedter D, Siebert U, Oertel WH, Ulm G, Dodel R. Cost of illness and its predictors for Parkinson’s disease in Germany. Pharmacoeconomics. 2005;23:817–36.

    Article  PubMed  Google Scholar 

  45. Pechevis M, Clarke CE, Vieregge P, Khoshnood B, Deschaseaux-Voinet C, Berdeaux G, Ziegler M, Trial Study Group. Effects of dyskinesias in Parkinson’s disease on quality of life and health-related costs: a prospective European study. Eur J Neurol. 2005;12:956–63.

    Article  CAS  PubMed  Google Scholar 

  46. Ara R, Brazier J. Predicting the short form-6D preference-based index using the eight mean short form-36 health dimension scores: estimating preference-based health-related utilities when patient level data are not available. Value Health. 2009;12:346–53.

    Article  PubMed  Google Scholar 

  47. Nutt JG, Obeso JA, Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson’s disease. Trends Neurosci. 2000;23:S109–15.

    Article  CAS  PubMed  Google Scholar 

  48. Davis KL, Edin HM, Allen JK. Prevalence and cost of medication nonadherence in Parkinson’s disease: evidence from administrative claims data. Mov Disord. 2010;25:474–80.

    Article  PubMed  Google Scholar 

  49. Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson’s disease. Mov Disord. 2005;20:1502–7.

    Article  PubMed  Google Scholar 

  50. Kulkarni AS, Balkrishnan R, Anderson RT, Edin HM, Kirsch J, Stacy MA. Medication adherence and associated outcomes in medicare health maintenance organization-enrolled older adults with Parkinson’s disease. Mov Disord. 2008;23:359–65.

    Article  PubMed  Google Scholar 

  51. College of Health Insurance Companies (College voor Zorgverzekeringen). http://www.medicijnkosten.nl. Date last accessed: 16 July 2010.

  52. Munneke M, Nijkrake MJ, Keus SH, Kwakkel G, Berendse HW, Roos RA, Borm GF, Adang EM, Overeem S, Bloem BR, ParkinsonNet Trial Study Group. Efficacy of community-based physiotherapy networks for patients with Parkinson’s disease: a cluster-randomised trial. Lancet Neurol. 2010;9:46–54.

    Article  PubMed  Google Scholar 

  53. ParkinsonNet. http://www.parkinsonnet.nl. Date last accessed: 15 July 2011.

  54. College of Health Insurance Companies. (College voor Zorgverzekeringen). http://www.gipdatabank.nl. Date last accessed: 30 December 2011.

  55. Briggs AH, Claxton K, Sculpher MJ, editors. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.

    Google Scholar 

  56. Biglan KM, Schwid S, Eberly S, Blindauer K, Fahn S, Goren T, Kieburtz K, Oakes D, Plumb S, Siderowf A, Stern M, Shoulson I, Parkinson Study Group. Rasagiline improves quality of life in patients with early Parkinson’s disease. Mov Disord. 2006;21:616–23.

    Article  PubMed  Google Scholar 

  57. Haycox A, Armand C, Murteira S, Cochran J, Francois C. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson’s disease in the UK setting: an economic Markov model evaluation. Drugs Aging. 2009;26:791–801.

    Article  PubMed  Google Scholar 

  58. Hoerger TJ, Bala MV, Rowland C, Greer M, Chrischilles EA, Holloway RG. Cost effectiveness of pramipexole in Parkinson’s disease in the US. Pharmacoeconomics. 1998;14:541–57.

    Article  CAS  PubMed  Google Scholar 

  59. Elm JJ, Kamp C, Tilley BC, Guimaraes P, Fraser D, Deppen P, Brocht A, Weaver C, Bennett S, NINDS NET-PD Investigators and Coordinators. Self-reported adherence versus pill count in Parkinson’s disease: the NET-PD experience. Mov Disord. 2007;22:822–7.

    Article  PubMed  Google Scholar 

  60. Leopold NA, Polansky M, Hurka MR. Drug adherence in Parkinson’s disease. Mov Disord. 2004;19:513–7.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was funded by GlaxoSmithKline.

Financial disclosures/conflict of interest

C.B. is an employee of GlaxoSmithKline and is a visiting researcher at the University of Groningen. M.B. and M.D. are employees of GlaxoSmithKline. M.P. has received grants, honoraria and travel stipends from various pharmaceutical companies, including those interested in the topic covered in this article. A.N. and J.v.B. have no relevant conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Department of Pharmacy, Unit of PharmacoEpidemiology and PharmacoEconomics (PE2), University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands

    Job F. M. van Boven, Cornelis Boersma & Maarten J. Postma

  2. Anovak Services, Apeldoorn, The Netherlands

    Annoesjka Novak

  3. GlaxoSmithKline, Zeist, The Netherlands

    Maurice T. Driessen, Cornelis Boersma & Maarten M. Boomsma

Authors
  1. Job F. M. van Boven
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annoesjka Novak
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maurice T. Driessen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cornelis Boersma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maarten M. Boomsma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maarten J. Postma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Job F. M. van Boven.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Boven, J.F.M., Novak, A., Driessen, M.T. et al. Economic Evaluation of Ropinirole Prolonged Release for Treatment of Parkinson’s Disease in The Netherlands. Drugs Aging 31, 193–201 (2014). https://doi.org/10.1007/s40266-013-0150-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-013-0150-4

Keywords

Search

Navigation